Objective Type 2 diabetes mellitus (T2DM) is closely related to sarcopenic obesity (SO).
Body composition measurement including body weight, body mass index, waist …

Abstract Objective Sodium-glucose cotransporter-2 (SGLT-2) inhibitors therapies were
reported to affect adipose tissue distribution. However, the available evidence about the …

Objective Sarcopenia has been recognized as the third category of disabling complications
in patients with type 2 diabetes mellitus (T2DM), in addition to micro-and macrovascular …

Background: We aimed to assess the safety and efficiency of the novel sodium glucose co-
transporter 2 (SGLT2) inhibitor in combinations with insulin for type 1 and type 2 diabetes …

Introduction The obesity epidemic is closely linked to the rising prevalence of type 2
diabetes (T2D). Body weight reduction remains an important challenge in patients with T2D …

Background: The goals of improving quality of life and increasing longevity are receiving
growing amounts of attention. Body weight and lipid metabolism are closely related to …

SGLT2 (sodium-glucose cotrans-porter type 2) inhibitors are a new class of drugs which
reversibly block the glucose reabsorption that occurs in the kidneys. Since their mechanisms …

To assess the efficacy and safety of the SGLT-2 inhibitors as adjunct therapy to insulin in
T1DM, clinical trials indexed in PubMed, Cochrane Library, EMbase from inception through …

The prevalence of obesity in Asia is of epidemic proportions, with an estimated 1 billion
overweight/obese individuals in the region. The majority of patients with type 2 diabetes …

Purpose To evaluate the efficacy and safety of combination therapy with sodium–glucose
cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists in …